drugset
drugset / Trial / NCT03040427

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427 ↗

Phase 4 Terminated 12 enrolled The Cleveland Clinic Avid Radiopharmaceuticals · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

Timeline

Start
2017-01
Primary completion
2019-08-21
Completion
2019-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject florbetapir F 18 Diagnostic / imaging agent — Other

Indications

amyloidosis